TRAF2 and plasma cell myeloma: Among the rare paradoxical effects of TRAF2, TRAF2 inactivating mutations increase alternative NF-κB pathway activation in mantle cell lymphoma, diffuse large B-cell lymphoma and multiple myeloma [79, 80].